Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera in Refractory/Relapsing/Chronic ITP
NCT00475423Phase 2Completed
- Sponsor
- Roche
- Start
- May 2007
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in immune thrombocytopenia (ITP), sponsored by Roche. Started May 2007; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00475423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475423.